 Experience with the high dosage of tirofiban Several studies performed following the completion of TARGET strongly suggested that the 10 μgkg bolus dose of tirofiban is inadequate3. The TARGET dosing regimen of tirofiban inhibited 20 uMADP-mediated platelet aggregation only by 60-66 from 15-60 minutes after onset of treatment when tested with PPACK as a sample anticoagulant, and as a result of rapid tissue redistribution yielded a tirofiban plasma level of 35-40 ngmL4. Abciximab, as it was dosed in the TARGET trial, produced a 90-95 inhibition of platelet aggregation in this same time period. This difference in extent of platelet aggregation inhibition was proposed as the reason why more procedure-related ischemic events occurred among subjects receiving tirofiban in the TARGET trial. 